Targeted MRD Growth Adela’s tissue-free MRD and MCED testing offers universal accessibility for cancer monitoring, presenting a compelling opportunity to expand adoption across oncology clinics and community hospitals that lack tumor tissue access, enabling broader payer coverage discussions and potential channel partnerships.

Strategic Partnerships Recent collaborations with Dendi and notable investor backing (OrbiMed funding) indicate a favorable market stance for co-development and co-commercialization. Leverage these relationships to access integrated sales motions, joint business planning, and accelerated market entry in validation-ready indications.

Clinical Validation Signals Published validation for head and neck cancer MRD and immunotherapy response monitoring, plus upcoming MCED studies, create strong talking points for payer and hospital procurement conversations, highlighting clinical utility, recurrence prediction, and treatment decision support.

Expansion Through Events Active participation in major oncology conferences (ASCO 2025 and 2026) demonstrates a tempo for evidence dissemination and clinician engagement, suggesting a cadence for targeted outreach to key KOLs and hospital systems following conference sessions.

Financial Momentum Revenue in the high hundreds of millions with a $48M funding milestone signals scale and investment readiness, enabling sales teams to frame ROI with real-world performance, expand into additional cancer indications, and pursue enterprise-wide contracts with BI/biotech procurement teams.